Can an herbal formula boost lung cancer treatment?
NCT ID NCT07390565
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding Yishen Qutong Granules, a traditional Chinese medicine, to standard chemo-immunotherapy can improve outcomes for people with extensive-stage small cell lung cancer. About 308 participants will receive either the herbal granules or a placebo alongside their regular treatment. The goal is to see if the granules help control the disease, improve quality of life, and reduce side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Yishen Qutong Granules (a traditional Chinese medicine formula)
What this could lead to
If it works, this could offer a way to reduce chemotherapy side effects and improve quality of life and survival for people with advanced small cell lung cancer.
What could go wrong
This is an early-stage trial with no phase designation, so results are uncertain. The herbal granules may not provide added benefit over standard therapy, and interactions with chemo-immunotherapy are not well understood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER (SCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences/Peking Union Medical College
Beijing, Chaoyang, 100021, China